Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
556 stopped studies mapped to Acute Myeloid Leukemia and descendants · 90% state a reason
Over the 556 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05275439 | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML | Phase 1 | terminated | Mar 11, 2022 | Shattuck Labs, Inc. | Development discontinued | Other (stated, no rule matched) |
| NCT03547115 | A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell… | Phase 1 | terminated | Jun 6, 2018 | MEI Pharma, Inc. | Business reasons, not related to safety or efficacy results. | Safety / toxicity |
| NCT04347616 | Natural Killer-cell Therapy for Acute Myeloid Leukemia(NK4AML) | Phase 1 / Phase 2 | terminated | Apr 15, 2020 | Radboud University Medical Center | Stop funding | Funding |
| NCT06626633 | 2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML | Phase 1 | suspended | Oct 4, 2024 | University of Maryland, Baltimore | Pharmaceutical Company withdrew support and investigational product | Sponsor / business decision |
| NCT03404193 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid… | Phase 2 | terminated | Jan 19, 2018 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT03772925 | Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute… | Phase 1 | terminated | Dec 12, 2018 | National Cancer Institute (NCI) | Drug supply issues | Drug supply |
| NCT05170828 | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | Phase 1 | withdrawn | Dec 28, 2021 | Ossium Health, Inc. | Change in Study Design | Other (stated, no rule matched) |
| NCT04964505 | Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute… | Phase 1 | terminated | Jul 16, 2021 | Brian Jonas | Sponsor decision | Sponsor / business decision |
| NCT03467386 | Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in… | Phase 1 | suspended | Mar 16, 2018 | City of Hope Medical Center | accrual goal | Enrollment / accrual |
| NCT04160052 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory… | Phase 1 / Phase 2 | terminated | Nov 12, 2019 | M.D. Anderson Cancer Center | \<75% participation | Other (stated, no rule matched) |
| NCT05654779 | CLL-1/CD33 Targeted LCAR-AMDR Cells in Patients With Relapsed or Refractory Acute Myeloid… | Phase 1 | terminated | Dec 16, 2022 | Institute of Hematology & Blood Diseases Hospital, China | Both the sponsors and collaborator are considering terminating the study | Other (stated, no rule matched) |
| NCT02381548 | Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory… | Phase 1 | terminated | Mar 6, 2015 | National Cancer Institute (NCI) | Other - Adverse Events | Safety / toxicity |
| NCT04230265 | Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic… | Phase 1 | terminated | Jan 18, 2020 | AvenCell Europe GmbH | business decision by sponsor | Sponsor / business decision |
| NCT04150029 | A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit…(STIMULUS-AML1) | Phase 2 | terminated | Nov 4, 2019 | Novartis Pharmaceuticals | Novartis made a decision to early terminate the sabatolimab clinical development program, including… | Other (stated, no rule matched) |
| NCT05799079 | Decitabine and Cedazuridine in Combination With Venetoclax for the Treatment of Patients… | Phase 2 | terminated | Apr 5, 2023 | Sanjay Mohan | Study was terminated early due to lack of accrual and loss of funding. | Enrollment / accrual |
| NCT03760523 | Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Nov 30, 2018 | H. Lee Moffitt Cancer Center and Research Institute | Toxicity -Two DLT events occurred | Safety / toxicity |
| NCT04240002 | A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and… | Phase 1 / Phase 2 | terminated | Jan 27, 2020 | Astellas Pharma Global Development, Inc. | The study was terminated due to enrollment challenges. | Enrollment / accrual |
| NCT03055286 | Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients | Phase 1 / Phase 2 | terminated | Feb 16, 2017 | JW Pharmaceutical | business/strategic reason | Sponsor / business decision |
| NCT05361057 | Efficacy of Venetoclax Based Regimen in Prevention Relapse of Consecutive MRD Positive… | Phase 2 | terminated | May 4, 2022 | Institute of Hematology & Blood Diseases Hospital, China | The research center has conducted a more comprehensive study. | Other (stated, no rule matched) |
| NCT06709131 | A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/Refractory…(CT0991) | Phase 1 | suspended | Nov 29, 2024 | He Huang | Product manufacturing process improvement | Drug supply |
| NCT06454409 | Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients… | Phase 1 | suspended | Jun 12, 2024 | City of Hope Medical Center | resources | Other (stated, no rule matched) |
| NCT07004816 | The Mutation Profile and Prognosis in AML With IDH1/2 Mutation | — | terminated | Jun 4, 2025 | Institute of Hematology & Blood Diseases Hospital, China | Adapted the plan | Other (stated, no rule matched) |
| NCT04937166 | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological… | Phase 1 | terminated | Jun 23, 2021 | Kahr Medical | Slow enrolment | Enrollment / accrual |
| NCT04874194 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid… | Phase 1 / Phase 2 | terminated | May 5, 2021 | M.D. Anderson Cancer Center | The study terminated early because the company was longer providing the investigational product. | Sponsor / business decision |
| NCT04511130 | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant(ARTEMIS) | Phase 2 | terminated | Aug 13, 2020 | Marker Therapeutics, Inc. | Despite a plan to enroll \~195-210 participants, the ARTEMIS study was closed due to the long… | Drug supply |
| NCT04623216 | Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of… | Phase 1 / Phase 2 | terminated | Nov 10, 2020 | Novartis Pharmaceuticals | Study was stopped following a strategic decision from the Sponsor. It was not based on any safety… | Safety / toxicity |
| NCT04678336 | CD123 Redirected T Cells for AML in Pediatric Subjects | Phase 1 | terminated | Dec 21, 2020 | University of Pennsylvania | Administrative reasons | Other (stated, no rule matched) |
| NCT03940352 | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia… | Phase 1 | terminated | May 7, 2019 | Novartis Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT04702425 | VOB560-MIK665 Combination First in Human Trial in Patients With Hematological… | Phase 1 | terminated | Jan 8, 2021 | Novartis Pharmaceuticals | Business reasons | Sponsor / business decision |
| NCT05358808 | ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded…(ACHIEVE) | Phase 2 | terminated | May 3, 2022 | TC Biopharm | The Trial was early terminated due to deficiencies in the Achieve Protocol: V8.0 dated 19 January… | Other (stated, no rule matched) |
| NCT05961839 | Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic… | Phase 1 | terminated | Jul 27, 2023 | Schrödinger, Inc. | Company decision | Sponsor / business decision |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With…(ISAKIDS) | Phase 2 | terminated | Mar 4, 2019 | Sanofi | Study was prematurely stopped due to sponsor decision (stage 2 efficacy criteria not met); not due… | Safety / toxicity |
| NCT02438761 | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid…(5) | Phase 2 | terminated | May 8, 2015 | Institut Curie | No objective response was observed at the first step. The treatment was considered ineffective,… | Other (stated, no rule matched) |
| NCT03769532 | MRD-guided Treatment in NPM1mut AML Patients(PEMAZA) | Phase 2 | terminated | Dec 7, 2018 | Technische Universität Dresden | Feasibility | Other (stated, no rule matched) |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With… | Phase 1 / Phase 2 | terminated | Nov 7, 2024 | Sutro Biopharma, Inc. | Terminated Early | Other (stated, no rule matched) |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in… | Phase 1 / Phase 2 | terminated | Jul 18, 2024 | Sanofi | Early discontinuation based on strategic sponsor decision not driven by any safety concerns | Safety / toxicity |
| NCT05817058 | First-in-Human Dose Escalation Study of AFM28 in Patients With Relapsed/Refractory Acute… | Phase 1 | terminated | Apr 18, 2023 | Affimed GmbH | As decided by sponsor | Other (stated, no rule matched) |
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | N/A | withdrawn | Aug 1, 2023 | Neena Kapoor, M.D. | No funding available. | Funding |
| NCT04789408 | Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | terminated | Mar 9, 2021 | Kite, A Gilead Company | Study was terminated due to futility | Efficacy / futility |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell… | Phase 2 | terminated | Nov 7, 2017 | Roswell Park Cancer Institute | Futility analysis determined closure | Efficacy / futility |
| NCT05153330 | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With… | Phase 1 | terminated | Dec 10, 2021 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT05442580 | CART-38 in Adult AML and MM Patients | Phase 1 | terminated | Jul 5, 2022 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and… | Phase 1 | withdrawn | Aug 30, 2022 | Janssen Research & Development, LLC | Business Decision | Sponsor / business decision |
| NCT03724084 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute… | Phase 1 / Phase 2 | terminated | Oct 30, 2018 | National Cancer Institute (NCI) | Other - Study agent no longer available | Other (stated, no rule matched) |
| NCT05248685 | Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute… | Phase 1 | withdrawn | Feb 21, 2022 | Beijing Boren Hospital | no patients | Other (stated, no rule matched) |
| NCT06128044 | CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With…(AMpLify) | Phase 1 | terminated | Nov 13, 2023 | Caribou Biosciences, Inc. | Sponsor Decision - Pipeline Reprioritization | Sponsor / business decision |
| NCT06449482 | Selinexor、Venetoclax and Azactidine in the Treatment of ND AML Patients Who Are Not… | Phase 1 / Phase 2 | terminated | Jun 10, 2024 | Institute of Hematology & Blood Diseases Hospital, China | The number of participants in the study did not meet expectations | Other (stated, no rule matched) |
| NCT06572631 | Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for… | Phase 1 | withdrawn | Aug 27, 2024 | City of Hope Medical Center | cprmc withdrawn | Other (stated, no rule matched) |
| NCT04752163 | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of… | Phase 1 / Phase 2 | terminated | Feb 12, 2021 | M.D. Anderson Cancer Center | supporting/funding source decided to de-prioritize and stop development of DS-1594 | Funding |
| NCT03537599 | Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute… | Phase 1 / Phase 2 | terminated | May 25, 2018 | Sumithira Vasu | Poor acccrual | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Mar 18, 2026source: clinicaltrials